SCHEMBL5405835

SCHEMBL5405835

COC(=O)c1ccc(CNC(=O)c2ccc3[nH]ncc3c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.68
NAMPT P43490 2/20 0.58
ROCK2 O75116 6/20 0.58
METTL3 Q86U44 1/20 0.56
CYP2C9 P11712 1/20 0.54
MAPK1 P28482 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
ROCK1 Q13464 5/20 0.50
MAOA P21397 1/20 0.50
RPS6KA5 O75582 1/20 0.50
PRKACA P17612 1/20 0.50
RPS6KB1 P23443 1/20 0.50
PRKX P51817 1/20 0.50
PRKG2 Q13237 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
SGK2 Q9HBY8 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441326 0.91 MAOB (0.79) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5412553 0.89 MAOB (0.67) MAOBROCK2METTL3MAPK1NPC1
SCHEMBL5406113 0.88 MAOB (0.71) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5409324 0.86 MAOB (0.72) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5413102 0.85 MAOB (0.71) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5417278 0.85 MAOB (0.71) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5419152 0.85 MAOB (0.67) MAOBROCK2METTL3MAOAMEN1
SCHEMBL5179231 0.85 MAOB (0.70) MAOBNAMPTROCK2METTL3MAPK1
SCHEMBL5412828 0.85 ROCK2 (0.68) MAOBROCK2METTL3MAPK1NPC1
SCHEMBL5412495 0.85 MAOB (0.67) MAOBNAMPTROCK2METTL3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA MAOB 2025/4885NAMPT 1770/4885ROCK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.